Diseases / Vitiligo
Vitiligo
DiseaseVitiligo is a chronic pigmentary disorder in which melanocytes are destroyed, causing depigmented patches of skin and sometimes hair. It is often associated with autoimmune mechanisms.
- Trials
- 289
- Recruiting
- 27
- Completed
- 117
- With results
- 26
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | 1 | 1 | — | 2 | — | — | — | 1 | 6 |
| Phase 1 | 2 | — | — | 4 | 5 | — | — | — | 4 | 15 |
| Phase 1/2 | — | 2 | — | 1 | 2 | — | — | — | 1 | 6 |
| Phase 2 | 6 | 1 | — | 5 | 23 | 4 | 1 | — | 8 | 48 |
| Phase 2/3 | 2 | 2 | — | — | 3 | 3 | 1 | — | 1 | 12 |
| Phase 3 | 1 | 1 | — | 3 | 9 | — | 1 | — | 1 | 16 |
| Phase 4 | 2 | 1 | 1 | 2 | 9 | — | 1 | — | 6 | 22 |
| Not applicable | 7 | 7 | — | 1 | 40 | 8 | 2 | 1 | 34 | 100 |
| Unknown | 6 | 6 | 1 | 3 | 24 | 2 | — | — | 22 | 64 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Vitiligo | 6 | 15 | 6 | 48 | 12 | 16 | 22 | 100 | 64 | 289 |
| Psoriasis | — | — | — | 2 | — | — | — | 3 | 15 | 20 |
| Dermatitis, Atopic | — | — | — | 1 | — | — | — | 3 | 14 | 18 |
| Alopecia Areata | — | 1 | — | 1 | — | — | — | 2 | 12 | 16 |
| Autoimmune Diseases | — | — | — | 1 | — | — | — | 4 | 4 | 9 |
| Hidradenitis Suppurativa | — | — | — | 1 | — | — | — | 1 | 7 | 9 |
| Skin Diseases | 1 | 1 | — | 2 | — | — | — | 2 | 2 | 8 |
| Pigmentation Disorders | 1 | — | — | 3 | 1 | — | — | 2 | — | 7 |
| Eczema | — | — | — | 2 | — | — | — | 1 | 2 | 5 |
| Graves Disease | — | — | — | — | — | — | — | — | 5 | 5 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Cairo University | 20 | 0 |
| 2 | Assiut University | 16 | 0 |
| 3 | Centre Hospitalier Universitaire de Nice | 16 | 5 |
| 4 | Sohag University | 10 | 1 |
| 5 | Henry Ford Health System | 7 | 2 |
| 6 | Incyte Corporation | 7 | 3 |
| 7 | University Hospital, Bordeaux | 7 | 1 |
| 8 | Xijing Hospital | 6 | 0 |
| 9 | The Catholic University of Korea | 5 | 0 |
| 10 | University of British Columbia | 5 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Phototherapy | 12 |
| 2 | Percutaneous Collagen Induction | 11 |
| 3 | Tacrolimus | 11 |
| 4 | Lasers, Excimer | 8 |
| 5 | ruxolitinib | 8 |
| 6 | afamelanotide | 5 |
| 7 | Blood Specimen Collection | 5 |
| 8 | Fluorouracil | 5 |
| 9 | Ointments | 5 |
| 10 | Dermabrasion | 4 |
Evidence
- Results reported
- 22.2%26 of 117 completed
- Published
- 16.2%19 of 117 completed
- Primary endpoint met
- 86.7%13 of 15 analyses
- Median months to report
- 12.5
Documents disclosed
Trial profile
- Median enrollment
- 40
- Median duration
- 18.8months
- Countries
- 49
- Study sites
- 989
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 50
- Phase 1
- 36
- Phase 1/2
- 63
- Phase 2
- 33
- Phase 2/3
- 29
- Phase 3
- 250
- Phase 4
- 30
- Not applicable
- 29
- Unknown
- 125
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Nice | France | 26 |
| 2 | Bordeaux | France | 19 |
| 3 | Detroit | United States | 17 |
| 4 | New York | United States | 16 |
| 5 | Worcester | United States | 16 |
| 6 | Cairo | Egypt | 14 |
| 7 | Boston | United States | 13 |
| 8 | Irvine | United States | 11 |
| 9 | Xi'an | China | 10 |
| 10 | Amsterdam | Netherlands | 9 |
Terminations
- Terminated
- 17
- Withdrawn
- 6
- Suspended
- 1
- Stopped for recruitment
- 1.4%4 of 289 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05607316 Withdrawn | Withdrawn | Unable to secure funding. | 2028-11-01 |
| NCT06446063 Terminated | Terminated | Lack of recruitment | 2025-10-31 |
| NCT06493578 Terminated | Terminated | Business Decision | 2025-09-30 |
| NCT05503368 Suspended | Suspended | lack of availability of the needed kits | 2024-04-30 |
| NCT04734704 Terminated | Terminated | target number of patients not reached and disabling team changes | 2024-01-23 |
| NCT04858152 Withdrawn | Withdrawn | Logistic issues | 2023-08-15 |
| NCT04374435 Terminated | Terminated | The blistering device used for harvesting the third arm was discontinued by the manufacturer. | 2022-05-01 |
| NCT04774809 Terminated | Terminated | terminated by sponsor | 2022-03-21 |
| NCT04271501 Terminated | Terminated | Suspended and Terminated to focus on CTP009 (NCT04547998) Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions | 2021-08-24 |
| NCT04811131 Terminated | Terminated | Sponsor Decision | 2021-08-09 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: